The historical rank and industry rank for Pheton Holdings's Gross Margin % or its related term are showing as below:
PTHL'
s Gross Margin % Range Over the Past 10 Years
Min: 74.88 Med: 82.06 Max: 84.07
Current: 79.37
During the past 4 years, the highestGross Margin % of Pheton Holdings was 84.07%. The lowest was 74.88%. And the median was 82.06%.
PTHL's Gross Margin % is ranked better than 90.07% of 806
companies
in the Medical Devices & Instruments industry
Industry Median: 52.7
vs PTHL: 79.37
Pheton Holdings had a gross margin of 84.03% for the quarter that ended in Dec. 2024 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Pheton Holdings was 0.00% per year.
Pheton Holdings Gross Margin % Historical Data
The historical data trend for Pheton Holdings's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pheton Holdings's Gross Margin %
For the Medical Devices subindustry, Pheton Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pheton Holdings's Gross Margin % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pheton Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Pheton Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Pheton Holdings had a gross margin of 84.03% for the quarter that ended in Dec. 2024 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Pheton Holdings Gross Margin % Related Terms
Thank you for viewing the detailed overview of Pheton Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PTHL has been successfully added to your